Swiss National Bank grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 0.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,697,900 shares of the biopharmaceutical company's stock after buying an additional 5,900 shares during the quarter. Swiss National Bank owned 0.30% of Gilead Sciences worth $310,032,000 as of its most recent SEC filing.
A number of other hedge funds have also recently modified their holdings of GILD. M&G Plc acquired a new position in Gilead Sciences in the 1st quarter worth about $7,082,000. Nicolet Advisory Services LLC lifted its position in shares of Gilead Sciences by 12.9% during the 1st quarter. Nicolet Advisory Services LLC now owns 2,941 shares of the biopharmaceutical company's stock valued at $206,000 after buying an additional 336 shares in the last quarter. Allstate Corp grew its stake in Gilead Sciences by 4.6% in the 1st quarter. Allstate Corp now owns 4,249 shares of the biopharmaceutical company's stock valued at $311,000 after acquiring an additional 187 shares during the period. Edgestream Partners L.P. increased its holdings in Gilead Sciences by 447.6% in the 1st quarter. Edgestream Partners L.P. now owns 52,973 shares of the biopharmaceutical company's stock worth $3,880,000 after acquiring an additional 43,300 shares in the last quarter. Finally, Covestor Ltd raised its position in Gilead Sciences by 20.7% during the first quarter. Covestor Ltd now owns 3,225 shares of the biopharmaceutical company's stock worth $236,000 after acquiring an additional 553 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.
Gilead Sciences Trading Down 4.0 %
Shares of NASDAQ GILD traded down $3.71 during mid-day trading on Friday, reaching $88.40. 11,454,518 shares of the company's stock were exchanged, compared to its average volume of 6,971,457. The company's 50-day moving average is $86.68 and its 200-day moving average is $76.11. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.82 and a current ratio of 1.26. The firm has a market capitalization of $110.17 billion, a price-to-earnings ratio of 982.22, a PEG ratio of 2.72 and a beta of 0.17. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion for the quarter, compared to analysts' expectations of $7.01 billion. During the same quarter in the prior year, the company posted $2.29 earnings per share. Gilead Sciences's revenue for the quarter was up 7.0% compared to the same quarter last year. Analysts expect that Gilead Sciences, Inc. will post 4.38 EPS for the current fiscal year.
Gilead Sciences Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.48%. The ex-dividend date is Friday, December 13th. Gilead Sciences's payout ratio is 3,422.22%.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on GILD shares. Cantor Fitzgerald lifted their target price on shares of Gilead Sciences from $70.00 to $80.00 and gave the company a "neutral" rating in a research report on Thursday, November 7th. Wolfe Research initiated coverage on Gilead Sciences in a report on Friday. They issued an "outperform" rating and a $110.00 price objective on the stock. Truist Financial increased their target price on Gilead Sciences from $83.00 to $97.00 and gave the company a "hold" rating in a report on Friday, November 8th. Citigroup started coverage on Gilead Sciences in a research note on Thursday. They issued a "buy" rating and a $125.00 price target on the stock. Finally, BMO Capital Markets increased their price objective on Gilead Sciences from $94.00 to $102.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and four have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $93.86.
Check Out Our Latest Stock Analysis on GILD
Insider Transactions at Gilead Sciences
In other news, insider Johanna Mercier sold 29,357 shares of the company's stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now owns 78,127 shares of the company's stock, valued at approximately $6,545,480.06. This represents a 27.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares of the company's stock, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 56,947 shares of company stock worth $4,968,674 over the last ninety days. Company insiders own 0.16% of the company's stock.
Gilead Sciences Company Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
